Insomnia Prevalent Among Cancer Patients Who Receive Chemotherapy
Posted on: Monday, 23 November 2009, 17:06 CST
University of Rochester study shows impact of care lingers for months
Three quarters of cancer patients and survivors treated with chemotherapy suffer insomnia or sleep disorders that often become chronic conditions, hindering patients' ability to fully recover, according to scientists at the University of Rochester Medical Center.
A study of 823 cancer patients showed they experienced sleep troubles at nearly three times the rate of the general population. The problem was more prevalent in younger patients and those with lung and breast cancers, according to the paper published online in the Journal of Clinical Oncology.
"These numbers are very high and something we can't ignore," said Oxana Palesh, Ph.D., M.P.H., research assistant professor of Radiation Oncology at the Medical Center's James P. Wilmot Cancer Center and lead author of the paper. "The good news is that insomnia is a very treatable problem that can be addressed quickly so it doesn't compound other symptoms."
Palesh reviewed data on patients who received chemotherapy between 1997 and 1999 at private practice medical oncology groups who were part of the National Cancer Institute's Community Clinical Oncology Program (CCOP.)
Patients answered questionnaires after their first two chemotherapy treatments. Responses to sleep-related questions showed that 37 percent of participants suffered from insomnia symptoms and another 43 percent had insomnia syndrome, as categorized by the Hamilton Depression Inventory, a widely used measure for symptoms of depression. These patients had difficulty falling asleep and staying asleep at least three days per week.
The challenge is that once people experience sleep problems and related fatigue, they begin taking naps and going to bed earlier, which perpetuates the problem and is counter-productive to getting restorative sleep at night, Palesh said.
Sleep problems are generally combined with patients complaints of fatigue and depression however, it has not been studied to determine the causes and impact on patients' quality of life.
---
On the Net:
Related Articles
- Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer After First-Line Chemotherapy
- Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients With Advanced Endometrial Cancer
- Review Examines the Use of Sirtex's SIR-Spheres(R) Microspheres in Patients With Hepatic Colorectal Cancer Metastases
- NCCN 12th Annual Conference: Clinical Practice Guidelines in Oncology & Quality Cancer Care(TM) to Be Held March 14 - 18, 2007 in Hollywood, Florida
- Community Oncology Alliance Refutes NBC Nightly News Story 'Cancer Docs Profit From Chemotherapy Drugs'
- Avantogen Oncology Inc. Announces Preliminary Results of a Dose Ranging Study of RP101 in Combination With Gemcitabine Chemotherapy in Patients With Advanced Pancreatic Cancer
- Phase II Clinical Trial of NeoPharm's LE-SN38 Initiated By NCI CALGB in Patients With Metastatic Colorectal Cancer; First Patients Treated
- Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Advanced Colorectal Cancer
- OvaRex MAb for Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery and Chemotherapy
User Comments (0)

RSS Feeds